Optimising use of data across a FTSE 100 global pharmaceutical company
Oaklin initiated and mobilised a programme of work to improve data access for scientists across early clinical research.
The Oaklin team mapped the current processes and produced an in-depth change assessment and defined the business case. Through Oaklin’s structured approach, we were able to produce prioritised plans for delivery.
Oaklin then successfully mobilised the 2-year programme, allowing the business to maximise the reuse of data and producing a mechanism that could be repeated across other research areas.